{"id":"conventional-ost","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reaction"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Immune response"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This therapy involves the use of osteogenic stem cells that differentiate into bone-forming osteoblasts, promoting endogenous bone regeneration. The stem cells secrete growth factors and extracellular matrix components that facilitate osteogenesis and integration with existing bone tissue. This approach is designed to enhance bone healing in defects or degenerative conditions.","oneSentence":"Conventional OST (Osteogenic Stem Cell Therapy) promotes bone formation and regeneration by utilizing osteogenic stem cells to stimulate new bone growth.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:07:40.246Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bone defects and fracture healing"}]},"trialDetails":[{"nctId":"NCT06287606","phase":"PHASE3","title":"A Phase 3 Clinical Trials for Bowel Preparation for Colonoscopy","status":"COMPLETED","sponsor":"Taejoon Pharmaceutical Co., Ltd.","startDate":"2023-08-29","conditions":"Bowel Preparation","enrollment":161},{"nctId":"NCT02706223","phase":"NA","title":"Testing and Treating Hepatitis C in Community Pharmacies","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2016-12","conditions":"Hepatitis C","enrollment":356},{"nctId":"NCT03483818","phase":"NA","title":"Pilot Trial of Directly Observed Anti HCV Therapy & Contingency Management in a Population on Opiate Substitute Therapy","status":"COMPLETED","sponsor":"NHS Tayside","startDate":"2015-11","conditions":"Hepatitis C","enrollment":152}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Control group"],"phase":"phase_3","status":"active","brandName":"Conventional OST","genericName":"Conventional OST","companyName":"Taejoon Pharmaceutical Co., Ltd.","companyId":"taejoon-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Conventional OST (Osteogenic Stem Cell Therapy) promotes bone formation and regeneration by utilizing osteogenic stem cells to stimulate new bone growth. Used for Bone defects and fracture healing.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}